GlassScriptPhysician profile
Joseph L Vanderlinden
NPI 1336162676
$2,115.89
in general payments reported to CMS, 2019-2025
8 companies · $74.00 in 2025
The $74.00 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2023: $1,869 · 2025: $74.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,832 · Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,832.14 |
| Food and Beverage | $111.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $932.14 | 2023 | Advantagerib |
| Alphatec Spine, INC | $915.73 | 2023 | Other - Miscellaneous |
| Medacta USA, INC. | $124.96 | 2021 | |
| Imperative Care, INC | $53.16 | 2025 | Symphony Catheter |
| Boston Scientific Corporation | $47.66 | 2021 | |
| Ethicon US, LLC | $21.40 | 2023 | Harmonic, Enseal |
| Philips North America LLC | $20.84 | 2025 | IV Other |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$314,920.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vanderlinden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.